Trials / Conditions / Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
5 registered clinical trials studyying Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Active Not Recruiting | Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early NCT02689440 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and C NCT02311998 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Ther NCT01751425 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic P NCT01746836 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia NCT00254423 | M.D. Anderson Cancer Center | Phase 2 |